Skip to main content
Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
42.37
+0.82 (1.97%)
At close: Mar 9, 2026, 4:00 PM EDT
42.38
+0.01 (0.02%)
After-hours: Mar 9, 2026, 6:56 PM EDT

Exelixis Revenue

In the year 2025, Exelixis had annual revenue of $2.32B with 6.98% growth. Exelixis had revenue of $598.66M in the quarter ending December 31, 2025, with 5.63% growth.

Revenue (ttm)
$2.32B
Revenue Growth
+6.98%
P/S Ratio
4.74
Revenue / Employee
$2,154,249
Employees
1,077
Market Cap
11.00B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20252.32B151.43M6.98%
Dec 31, 20242.17B338.49M18.49%
Dec 31, 20231.83B219.15M13.60%
Dec 31, 20221.61B176.09M12.27%
Dec 31, 20211.43B447.43M45.31%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Jazz Pharmaceuticals 4.27B
BioMarin Pharmaceutical 3.22B
Bio-Techne 1.22B
Madrigal Pharmaceuticals 958.40M
Ionis Pharmaceuticals 943.71M
BridgeBio Pharma 502.08M
ImmunityBio 113.29M
Praxis Precision Medicines 7.46M
Revenue Rankings

EXEL News

More News